Klastr zdraví

Klastr Zdraví je jedním ze šesti tematicky zaměřených klastrů – oblastí intervencí, které tvoří jádro obsahu 2. pilíře (více informací o struktuře programu Horizont Evropa zde). Obsah klastru, zaměření a očekávané výzvy pro roky 2021 - 20 22 definuje pracovní program (Work programme) věnovaný konkrétně oblasti zdraví. Informace o klastru zdraví, propojení podporovaných oblastí s politikami komise a synergie v rámci druhého pilíře jsou popsány také ve Strategickém plánu.
Klastr Zdraví se zaměřuje na ochranu a podporu zdraví a zdravého životního stylu, předcházení nemocem a snižování jejich dopadů na populaci, podporu transformace systémů zdravotní péče a podporu inovativního, udržitelného a globálně konkurenceschopného evropského zdravotnického průmyslu. Klastr Zdraví je rozdělen do šesti oblastí Destinations, v jejichž rámci budou v následujících letech vyhlašovány konkrétní výzvy.

1. Staying healthy in a rapidly changing society

People´s health care needs are different, depending on their age, stage of life and socioeconomic background. Their physical and mental health and well-being can be influenced by their individual situation as well as the broader societal context they are living in. Furthermore, health education and behaviour are important factors. Currently, more than 790 000 deaths per year in Europe are due to risk factors such as smoking, drinking, physical inactivity, and obesity. Upbringing, income, education levels, social and gender aspects also have an impact on health risks and how disease can be prevented. Moreover, people´s health can be impacted by a rapidly changing society, making it challenging to keep pace and find its way through new technological tools and societal changes, which both are increasing demands on the individual´s resilience. In order to leave no one behind, to reduce health inequalities and to support healthy and active lives for all, it is crucial to provide suitable and tailor-made solutions, including for people with specific needs.

1.1 Research and innovation activities

Research and innovation can provide a better understanding of specific health and care needs throughout the life course, including age-specific and sex/gender-specific needs as well as special needs of vulnerable population groups, and develop more effective solutions for health promotion and disease prevention, including for needs related to chronic health conditions, physical disabilities, mental disorders and disabilities, or age-related impairments. Research and innovation can help people, as well as communities, in developing innovative services, policies, guidelines and digital solutions, also ensuring that they are accessible, equitable and effective in preventing disease and promoting health. Furthermore, research and innovation can provide new evidences, methodologies and tools for increasing health literacy, improving adoption of healthy lifestyles and behaviours that prevent diseases and promote health, and empowering citizens to manage their health, including children and adolescents. Key to achieving these objectives is the availability and accessibility of realworld health data, which will require appropriate support by research and data infrastructures.

1.2 Expected Impacts

  • Citizens adopt healthier lifestyles and behaviours, make healthier choices and maintain longer a healthy, independent and active life with a reduced disease burden, including at old ages or in other vulnerable stages of life.
  • Citizens are able and empowered to manage better their own physical and mental health and well-being, monitor their health, and interact with their doctors and health care providers.
  • Citizens´ trust in knowledge-based health interventions and in guidance from health authorities is strengthened, including through improved health literacy (including at young ages), resulting in increased engagement in and adherence to effective strategies for health promotion, diseases prevention and treatment, including increased vaccination rates and patient safety.
  • Health policies and actions for health promotion and disease prevention are knowledge-based, people-centred and thus targeted and tailored to citizens' needs, and designed to reduce health inequalities.

1.3 Cross-cluster complementarities

2. CULTURE, CREATIVITY AND INCLUSIVE SOCIETY
Synergies on health inequalities, on other inequalities affecting health, or on citizens’ behaviour and engagement.
4. DIGITAL, INDUSTRY AND SPACE
Synergies on digital tools, telemedicine or smart homes.
5. CLIMATE, ENERGY AND MOBILITY
Synergies on urban health or on mitigating the impact of road traffic accidents and related injuries.
6. FOOD, BIOECONOMY, NATURAL RESOURCES, AGRICULTURE & ENVIRONMENT
Synergies on role of nutrition for health (incl. human microbiome, mal- and over-nutrition, safe food), personalised diets (incl. food habits in general and childhood obesity in particular) and the impact of food-related environmental stressors on human health (incl. marketing and consumer habits).

2. Living and working in a health-promoting environment

The environment we live and work in is a major determinant of our health and well-being. It has direct or indirect beneficial or adverse impact on our health and well-being. Environmental factors are estimated to account for almost 20 % of all deaths in Europe. Opinion surveys have shown that European citizens are concerned about the impact of pollution on their health. The impacting factors on both physical and mental health and wellbeing are not all identified nor their effects comprehensively understood and accounted for to support evidence-based policy- and decision-making. Furthermore, agreed methodologies to estimate health-related costs of exposure to environmental stressors are lacking.

2.1 Research and innovation activities

In order to achieve sustainable impacts, research and innovation must provide solid evidence and stimulate its uptake into a large number of environmental, occupational, social, economic, fiscal and health policies at the EU, national and regional level. Strong collaborations across sectors and with other Horizon Europe clusters dealing with issues such as “one health”, agriculture, food, environment, climate, mobility, security, urban planning, social inclusion and gender will be needed to ensure that maximal societal benefits will be reached. Likewise, international cooperation, including at science-policy level, will be key to drive forward research and innovation to tackle this challenge.

2.2 Expected Impacts

  • Policy-makers and regulators are aware and well informed about environmental, socioeconomic and occupational risk factors as well as health-promoting factors across society.
  • Environmental, occupational, social, economic, fiscal and health policies and practices at the EU, national and regional level are sustainable and based on solid scientific evidence. These include overarching policy frameworks such as the European Green Deal, the Chemical Strategy for Sustainability, the 8th Environment Action Programme, the EU Strategic Framework on Health and Safety at Work and the European Environment and Health Process led by the World Health Organization.
  • The upstream determinants of disease – related to choices in energy generation, agricultural practices, industrial production, land use planning, built environment and construction – are known, understood and reduced.
  • The health threats and burden resulting from hazardous chemicals and air, water and soil pollution and contamination is reduced, so that the related number of deaths and illnesses is substantially reduced by 2030.
  • Living and working environments in European cities and regions are healthier, more inclusive, safer, resilient and sustainable.
  • The adaptive capacity and resilience of populations and health systems in the EU to climate and environmental change-related health risks is strengthened.
  • Citizens’ health and well-being is protected and promoted, and premature deaths, diseases and inequalities related to environmental pollution and degradation are prevented.
  • Citizens understand better complex environment and health issues, and effective measures to address them and support related policies and regulations.

2.3 Cross-cluster complementarities

4. DIGITAL, INDUSTRY AND SPACE
Synergies on health-related space research and innovation for locationbased services, geo-observation and monitoring (e.g. of pollution); on health impact assessment (e.g. of biodiversity loss, infrastructures, urban planning, transport technologies, chemicals and other substances, incl. pollution and One Health AMR).
5. CLIMATE, ENERGY AND MOBILITY
Synergies on the surveillance, prediction and mitigation of the health impact of climate change, on the health impact of transport-related environmental pollution (such as air and noise pollution), on transport and mobility related risks on health, or on concepts/technologies for smart and healthy homes, rural areas and cities; on health impact assessment (e.g. of infrastructure, urban planning, transport, technologies, chemicals and other substances, incl. pollution) and on preventable environmental causes of diseases.
6. FOOD, BIOECONOMY, NATURAL RESOURCES, AGRICULTURE & ENVIRONMENT
Synergies on human biomonitoring, on healthy ecosystems and human habitats (incl. nature-based solutions for health and well-being), on the sustainable management of clean water, soil, air, and biodiversity; on health impact assessment (e.g. of infrastructure, urban planning, transport, technologies, chemicals and other substances, incl. pollution); and on preventable environmental causes of diseases.

3. Tackling diseases and reducing disease burden

Communicable and non-communicable diseases cause the greatest amounts of premature death and disability in the EU and worldwide. They pose a major health, societal and economic threat and burden. Many people are still suffering from these diseases and too often dying prematurely. Non-communicable diseases, including mental illnesses and neurodegenerative diseases, are responsible for up to 80 % of EU health care costs. These costs are spent on the treatment of such diseases that to a large extent are preventable. Furthermore, only around 3 % of the health care budgets are currently spent on preventive measures although there is a huge potential for prevention. Infectious diseases, including infections resistant to antimicrobials, remain a major threat to public health in the EU but also to global health security. Deaths caused by antimicrobial resistance (AMR) could exceed 10 million per year worldwide according to some predictions.

3.1 Research and innovation activities

There is an urgent need for research and innovation on new prevention, public health interventions, diagnostics, vaccines, pharmacological and non-pharmacological therapies, new antibiotics and alternatives to, antibiotics, as well as to improve existing prevention strategies to create tangible impacts, taking into account sex/gender-related issues and patient safety issues. To quickly advance research and innovation on these issues, international cooperation could be an opportunity to pool the best expertise and know-how available worldwide, to access world-class research infrastructures and to leverage critical scales of investments on priority needs through better alignment with other funders of international health research and innovation cooperation. The continuation of international partnerships and cooperation with international organisations is particularly needed to combat infectious diseases, including antimicrobial resistances and emerging epidemics and pandemics, to respond to major unmet needs for global health security, including the global burden of non-communicable diseases.

3.2 Expected Impacts

  • Health burden of diseases in the EU and worldwide is reduced through effective disease management, including through the development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centred solutions for health care. In particular, patients are diagnosed early and accurately and receive effective, cost-efficient and affordable treatment, including patients with a rare disease, due to effective translation of research results into new diagnostic tools and therapies.
  • Premature mortality from non-communicable diseases is reduced by one third (by 2030), mental health and well-being is promoted, and the voluntary targets of the WHO Global Action Plan for the Prevention and Control of NCDs 2013-2020 are attained (by 2025), with an immediate impact on the related disease burden (DALYs).
  • Health care systems benefit from strengthened research and innovation expertise, human capacities and know-how for combatting communicable and non-communicable diseases, including through international cooperation. In particular, they are better prepared to respond rapidly and effectively to health emergencies and are able to prevent and manage communicable diseases transmissions epidemics, including within healthcare settings.
  • Citizens benefit from reduced (cross-border) health threat of epidemics and AMR pathogens, in the EU and worldwide. In particular, the epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases are contained and hepatitis, waterborne diseases and other communicable diseases are being combated.
  • Patients and citizens are knowledgeable of disease threats, involved and empowered to make and shape decisions for their health, and better adhere to knowledge-based disease management strategies and policies (especially for controlling outbreaks and emergencies).

3.3 Cross-cluster complementarities

3. CIVIL SECURITY FOR SOCIETY
Synergies on health security/ emergencies (preparedness and response, medical counter measures, epidemic outbreaks/pandemics, One Health AMR, natural disasters and technological incidents, bioterrorism).
4. DIGITAL, INDUSTRY AND SPACE
Synergies on decision-support systems or on geo-observation and monitoring (e.g. of disease vectors, epidemics).
6. FOOD, BIOECONOMY, NATURAL RESOURCES, AGRICULTURE & ENVIRONMENT
Synergies on health security, One Health AMR (one health approach across human, animal/plant, soil/ water health), biodiscovery and biotechnology, personalised diets to reducing the burden of diseases.

4. Ensuring access to innovative, sustainable and high-quality health care

Health systems are affected by limitations in sustainability and resilience, challenges which have been reinforced by the COVID-19 crisis that has also revealed inequalities in access to high-quality health care services. Our health systems need to become more effective, efficient, accessible, fiscally and environmentally sustainable, and resilient in order to cope with public health emergencies, to adapt to environmental challenges like climate change and to contribute to social justice and cohesion. Therefore, the transformation and modernisation of our health systems will be one of the biggest challenges in the economic recovery-bound future, but it will also be a time of opportunity for generating evidence, taking advantage of digital and data-driven innovation and developing more flexible and equitable health systems.

4.1 Research and innovation activities

Research and innovation can help by supporting the development of innovative solutions for health care systems in all their various dimensions (e.g. governance and financing, resilience and preparedness for health emergencies and climate changes, education and training of the health workforce, health service provision and sustainability, interaction with patients and patient empowerment) and for policy-making (health in all policies). In addition, research and innovation can provide decision-makers with new evidence, methods and tools to implement successfully those innovative solutions into their health care systems. It will deliver solutions that are scalable and transferrable between different types of health care systems in different countries and provide knowledge supporting the transfer of solutions between countries. In turn this will help to improve the governance and resilience of health care systems as well as to allocate resources according to people’s needs and preferences while delivering fiscal and environmental sustainability to make sure those needs can be met in the long-term.

Special focus

  • Modernising health care systems in the EU, especially through a European public-public partnership on transforming health and care systems.
  • Improving the quality of health care along the entire health care continuum and being people-centred.
  • Supporting evidence-based health care decisions both for health care providers and policy-makers, fostering improved foresight and enabling sound planning of health care resources.
  • Development and uptake of innovative health care services and solutions, including environmentally sustainable ones that contribute to the European Green Deal.

4.2 Expected Impacts

  • Health and social care services and systems have improved governance mechanisms and are more effective, efficient, accessible, resilient, trusted and sustainable, both fiscally and environmentally. Health promotion and disease prevention will be at their heart, by shifting from hospital-centred to community-based, people-centred and integrated health care structures and successfully embedding technological innovations that meet public health needs, while patient safety and quality of services is increased.
  • Health care providers are trained and equipped with the skills and competences suited for the future needs of health care systems that are modernised, digitally transformed and equipped with innovative tools, technologies and digital solutions for health care. They save time and resources by integrating and applying innovative technologies, which better involve patients in their own care, by reorganising workflows and redistributing tasks and responsibilities throughout the health care system, and by monitoring and analysing corresponding health care activities.
  • Citizens are supported to play a key role in managing their own health care, informal carers (including unpaid carers) are fully supported (e.g. by preventing overburdening and economic stress) and specific needs of more vulnerable groups are recognised and addressed. They benefit from improved access to health care services, including financial risk protection, timely access to quality essential health care services, including safe, effective, and affordable essential medicines and vaccines.
  • Health policy and systems adopt a holistic approach (individuals, communities, organisations, society) for the evaluation of health outcomes and value of public health interventions, the organisation of health care, and decision-making.
  • The actions resulting from the calls under this destination will also create strong opportunities for synergies with the EU4Health programme and in particular to contribute to the goals under general objectives 1a “protecting people in the Union from serious cross-border threats to health and strengthening the responsiveness of health systems and coordination among the Member States to cope with those threats” and 3 “strengthening health systems by improving their resilience and resource efficiency, in particular through: i) supporting integrated and coordinated work between Member States; ii) promoting the implementation of best practices data sharing; iii) reinforcing the healthcare workforce; iv) tackling the implications of demographic challenges; and v) advancing digital transformation”.

4.3 Cross-cluster complementarities

2. CULTURE, CREATIVITY AND INCLUSIVE SOCIETY
Synergies on health economics and economic models, on costeffectiveness, fiscal sustainability and accessibility of healthcare, or on adaptation of public health systems to societal challenges (climate change, environmental degradation, migration, demographic change, emerging epidemics and One Health AMR) thereby contributing to building resilience.
3. CIVIL SECURITY FOR SOCIETY
Synergies on security of health care infrastructures, incl. digital health infrastructures, health systems preparedness and response to disasters and other emergencies, and quality and safety of medicine (counterfeit and substandard medicine, illicit drugs, One Health AMR).
4. DIGITAL, INDUSTRY AND SPACE
Synergies on cybersecurity of (public) health systems, products and infrastructures of digitalised health and care, or on health impact assessment (e.g. related to consumer products, working place innovation).

5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

Technology is a key driver for innovation in the health care sector. It can provide better and more cost-efficient solutions with high societal impact, tailored to the specific health care needs of the individual. However, novel tools, therapies, technologies and digital approaches face specific barriers and hurdles in piloting, implementing and scaling-up before reaching the patient, encountering additional challenges such as public acceptance and trust. Emerging and disruptive technologies offer big opportunities for transforming health care, thereby promoting the health and well-being of citizens. Unlocking this potential and harnessing the opportunities depends on the capacity to collect, integrate and interpret large amounts of data, as well as ensure compatibility with appropriate regulatory frameworks and infrastructures that will both safeguard the rights of the individual and of society and stimulate innovation to develop impactful solutions. In addition to existing European Research Infrastructures, the European Health Data Space will promote health-data exchange and facilitate cross-border research activities. This destination aims to promote the development of tools, technologies and digital solutions for treatments, medicines, medical devices and improved health outcomes, taking into consideration safety, effectiveness, appropriateness, accessibility, comparative value-added and fiscal sustainability as well as issues of ethical, legal and regulatory nature.

5.1 Research and innovation activities

Research and innovation are needed on the large spectrum of tools and technologies for biomedical research, prevention, diagnosis, therapy and monitoring. Managing benefits and risks of new technologies and due consideration of aspects of safety, effectiveness, inter-operability, appropriateness, accessibility, comparative value-added, affordability and sustainability (environmental, fiscal, socio-economic) and issues of ethical, societal, regulatory and legal nature will be crucial in order to boost the acceptability of these novelties and to translate these innovations into health policies, health and care systems, and clinical practice responsibly. Moreover, to provide high-quality health care and reduce health inequalities, end users’ engagement in multidisciplinary, cross-sectorial cooperation with key stakeholders (patients, health care providers and workforce, researchers, regulatory bodies, policy-makers, funders) could help addressing specific unmet needs for health tools, technologies and digital solutions with limited commercial interest but also designing and developing suitable health products and services tailored to needs of specific population groups including needs related to sex/gender or other aspects. Artificial Intelligence technologies have recently shown great promise for analysing high volumes of health data, with high potential for advancing biomedical research, personalised medicine and health care and for supporting health care systems in their clinical, organisational and logistical functions provided that relevant and consistent health data of high quality is available and accessible.

5.2 Expected Impacts

  • Europe’s scientific and technological expertise and know-how, its capabilities for innovation in new tools, technologies and digital solutions, and its ability to take-up, scale-up and integrate innovation in health care is world-class.
  • Citizens benefit from targeted and faster research resulting in safer, more efficient, costeffective and affordable tools, technologies and digital solutions for improved (personalised) disease prevention, diagnosis, treatment and monitoring for better patient outcome and well-being, in particular through increasingly shared health resources (interoperable data, infrastructure, expertise, citizen/patient driven co-creation).
  • The EU gains high visibility and leadership in terms of health technology development, including through international cooperation.
  • The burden of diseases in the EU and worldwide is reduced through the development and integration of innovative diagnostic and therapeutic approaches, personalised medicine approaches, digital and other people-centred solutions for health care.
  • Both the productivity of health research and innovation, and the quality and outcome of health care is improved thanks to the use of health data and innovative analytical tools, such as artificial intelligence (AI) supported decision-making, in a secure and ethical manner, respecting individual integrity and underpinned with public acceptance and trust.

5.3 Cross-cluster complementarities

4. DIGITAL, INDUSTRY AND SPACE
Synergies on digitalisation of the health sector, incl. health technologies, medical devices and key enabling technologies; assisted, autonomous, independent and empowered living; smart homes; decision support systems; health impact assessment (e.g. related to consumer products, working place innovation).

6. Maintaining an innovative, sustainable and globally competitive health industry

The health industry is a key driver for growth and has the capacity to provide health technologies to the benefit of patients and providers of health care services. The relevant value chains involve a broad variety of key players from supply, demand and regulatory sides. In addition, the path of innovation in health is long and complex. The development of novel health technologies is generally associated with uncertainties and market barriers due to expensive and risky development (e.g. attrition rate in pharmaceutical development), high quality and security requirements (e.g. clinical performance, safety, data privacy and cybersecurity) and market specificities (e.g. strong regulation, pricing and reimbursement issues). In addition, the growing concern about environmental issues is putting more pressure on this industry. Therefore, there is a need for research and innovation integrating various stakeholders to facilitate market access of innovative health technologies (medical technologies, pharmaceuticals, biotechnologies, digital health technologies).

6.1 Research and innovation activities

There is a convergence and a need for cross-sectorial research and innovation (integrating medical technologies, pharmaceuticals, biotechnologies, digital health and eHealth technologies) to strengthen the single market, including by implementing the Digital Single Market strategy, supporting the standardisation policy, driving innovation from the demand side and providing evidence and guidelines for stakeholders and regulators to ensure take-up of innovations supports sustainability (environmental, fiscal, socioeconomic) while fostering access and reducing health inequalities. The health sector is subjected to strict regulatory requirements that impose the demonstration of clinical benefit(s) and safety. This means additional development steps, uncertainties and a longer time to market. Support to studies for health assessment procedures, clinical performance demonstration, quality assurance schemes and standardisation are therefore important elements. Research and innovation is needed to develop new crosssectorial business models where health-related industry cooperates early with health care systems in the development of value-added products and services to enable an optimal uptake and deployment of innovative solutions as well as to achieve the triple aim of improving the patient experience of care (including quality and satisfaction), improving the health of populations, and reducing the per capita cost of health care.

6.2 Expected Impacts

  • Health industry in the EU is more competitive and sustainable, assuring European leadership in breakthrough health technologies and strategic autonomy in essential medical supplies and digital technologies, contributing to job creation and economic growth, in particular with small – and medium-sized enterprises (SMEs).
  • Health industry is working more efficiently along the value chain from the identification of needs to the scale-up and take-up of solutions at national, regional or local level, including through early engagement with patients, health care providers, health authorities and regulators ensuring suitability and acceptance of solutions.
  • European standards, including for operations involving health data, ensure patient safety and quality of healthcare services as well as effectiveness and interoperability of health innovation and productivity of innovators.
  • Citizens, health care providers and health systems benefit from a swift uptake of innovative health technologies and services offering significant improvements in health outcomes, while health industry in the EU benefit from decreased time-to-market.
  • Health security in the EU benefits from reliable access to key manufacturing capacity, including timely provision of essential medical supplies of particularly complex or critical supply and distribution chains, such as regards vaccines or medical radioisotopes.

6.3 Cross-cluster complementarities

4. DIGITAL, INDUSTRY AND SPACE
Synergies on industrial research and innovation infrastructures (pilot plants, testing and simulation facilities, open innovation hubs); additive manufacturing (3D/4D printing) and other production technologies (incl. bio manufacturing); safe, smart and sustainable materials.

Plán výzev

Destination 1. Staying healthy in a rapidly changing society

HORIZON-HLTH-2023-STAYHLTH-1.01: The Silver Deal - Person-centred health and care throughout the EU

  • Single-stage, RIA
  • Je nutné udržet zdravou stárnoucí společnost
  • Využití technologií
  • Velmi obecný popis

HORIZON-HLTH-2023-STAYHLTH-1.02: Towards a holistic support to children and adolescents’ health and care provisions in an increasingly digital society

  • Single-stage, RIA
  • Důraz na psychické zdraví dětí a adolescentů po Covidu
  • Vzdělávání dětí v oblasti zdraví a prevence

HORIZON-HLTH-2023-STAYHLTH- 1.04: Improving population level screening strategies and programmes for non-communicable diseases

  • Single-stage, CSA
  • Nové screeningové programy, včetně novorozeneckých

HORIZON-HLTH-2024-STAYHLTH- 1.05: Personalised prevention for noncommunicable diseases - addressing areas of unmet needs using multiple data sources

  • Two-stage, RIA
  • Personalizovaná prevence, digitální nástroje…
  • Zatím obecný popis

Destination 2. Living and working in a health-promoting environment

HORIZON-HLTH-2023-ENVHLTH- 2.01: Planetary health: understanding the links between environmental degradation and health impacts

  • Single-stage, RIA
  • Vztah mezi zhoršováním kvality životního prostředí a zdravím – velmi obecné

HORIZON-HLTH-2023-ENVHLTH- 2.02: Evidence-based interventions for promotion of mental and physical health in changing working environments (post-pandemic workplaces)

  • Single-stage, RIA
  • Vztah zdraví a pracovního prostředí, velmi obecné

HORIZON-HLTH-2023-ENVHLTH- 2.03: Research in support of identification and understanding of human health effects of endocrine disrupting chemicals

  • Single-stage, RIA
  • Zkoumání vlivu endokrinních disruptorů na zdraví

HORIZON-HLTH-2023-ENVHLTH- 2.04: Global coordination of exposome research

  • Single-stage, CSA
  • Vliv expozomu na zdraví

HORIZON-HLTH-2024-ENVHLTH- 2.05: Exposure to hazardous substances (including nanomaterials) or biological agents in occupational environments and adverse health outcomes

  • Single-stage, RIA
  • Expozice rizikovým substancím nejen v prostředí zaměstnání

HORIZON-HLTH-2024-ENVHLTH- 2.06: The role of environmental pollution in noncommunicable diseases: air, noise and light and hazardous waste pollution

  • Two-stage, RIA
  • Zkoumání vlivu člověkem znečištěného prostředí na zdraví, zatím formulováno velmi obecně

Destination 3. Tackling diseases and reducing disease burden

HORIZON-HLTH-2023-DISEASE- 3.01: Palliative and end-of-life care for non-cancer patients

  • Single-stage, RIA
  • Nové přístupy v paliativní léčbě, zkoumání přínosů pro pacienty a cost-effectiveness
  • Tvorba guidelines

HORIZON-HLTH-2023-DISEASE- 3.03: Interventions in urban environments to reduce NCD risk (GACD)

  • Single-stage, RIA
  • Globa Alliance for Chronic Diseases
  • Prevence nepřenosných nemocí v městském prostředí
  • Zatím dost vágní

HORIZON-HLTH-2023-DISEASE- 3.04: Broad spectrum anti-viral therapeutics for infectious diseases with epidemic potential (Pandemic preparedness research)

  • Single-stage, RIA
  • Vývoj širokospektrálních antivirotik

HORIZON-HLTH-2023-DISEASE- 3.05: Sustaining European Clinical Trial networks for pandemic preparedness and response through well-established coordination mechanisms between EU adaptive platform trials (CSA for pandemic preparedness research)

  • Single-stage, CSA
  • Koordinace mezi European Clinical Trials Networks – připravenost na pandemie

HORIZON-HLTH-2023-DISEASE- 3.06: Towards a European partnership on brain health

  • Single-stage, CSA
  • Spolupráce policy makers, funders, public bodies s cílem koordinace a zamezení duplikaci aktivit
  • Socio-ekonomické cíle, geografické rozprostření přes celou Evropu
  • Setkávání, výměna informací

HORIZON-HLTH-2023-DISEASE- 3.07: Relationship between infectious and noncommunicable diseases (Comorbidities - relationship between infectious pathogens and non-communicable diseases and its relevance to comorbidities)

  • Single-stage, RIA
  • Vztah mezi infekcemi a nepřenosnými nemocemi – demence, revmatoidní onemocnění, kardiovaskulární; kromě rakoviny
  • Preklinický i klinický výzkum, využití umělé inteligence

HORIZON-HLTH-2024-DISEASE- 3.08: Comparative effectiveness research for healthcare interventions in areas of high public health need

  • Two-stage, RIA
  • Nové typy intervencí (farmakologické, nefarmakologické, technologické)
  • Klinické studie – zkoumají mj. i cost-effectiveness, quality of life apod.
  • Zahrnutí pacientských organizací a SSH

HORIZON-HLTH-2024-DISEASE- 3.09: Contribution to the Global Research Collaboration for Infectious Disease Preparedness (GLOPID-R) coordinated funding initiative (co-programmed preparedness research at international level)

  • Two-stage, RIA
  • Témata budou definována Health Emergency Preparedness and Response Authority (HERA)

HORIZON-HLTH-2024-DISEASE- 3.10: Integrated management of multimorbidity (GACD)

  • Single-stage, RIA
  • Témata budou definována Global Alliance for Chronic Diseases (GACD)

HORIZON-HLTH-2024-DISEASE- 3.11: Adaptive platform trials for pandemic preparedness (Pandemic preparedness research)

  • Two-stage, RIA
  • Příprava adaptivních platforem pro klinické testy

HORIZON-HLTH-2024-DISEASE- 3.12: Maintaining the European partnership for pandemic preparedness (CSA for Pandemic preparedness research)

  • Single-stage, CSA
  • Podpora spolupráce v rámci European partnership for pandemic preparedness (vzniklo v rámci předchozího WP)

HORIZON-HLTH-2024-DISEASE- 3.13: Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders

  • Two-stage, RIA
  • Jednoduché testy na základě biomarkerů z tělesných tekutin – neurologická onemocnění

HORIZON-HLTH-2024-DISEASE-3.14: Tackling under-researched high-burden medical conditions

  • Two-stage, RIA
  • Málo prozkoumané nemoci – nediagnostikovaní pacienti
  • Mechanismy nemocí, preklinický, klinický výzkum, zahrnutí socioekonomických aspektů…

HORIZON-HLTH-2023-DISEASE- P5: European Partnership on Rare Diseases

  • Single-stage, Co-fund
  • 100 mil. EUR/projekt (1)

HORIZON-HLTH-2024-DISEASE- P6: European Partnership: One Health Anti-Microbial Resistance

  • Single-stage, Co-fund
  • 100 mil. EUR/projekt (1)

HERA – SPECIFIC TOPICS (Health Environment Reasearch Agenda for Europe)

HORIZON-HLTH-2023-DISEASE-3.15: research and innovation medical devices and protective equipment for better preparedness for cross-border health threats

  • X-stage, RIA
  • Nové pomůcky, technická řešení reagující na mezinárodní hrozby
  • Design, prototypy, nové využití existujících pomůcek

HORIZON-HLTH-2023-DISEASE-3.16: Pandemic Preparedness: in vitro diagnostic devices to tackle cross-border health threats

  • X-stage, RIA
  • In-vitro diagnostika mezinárodních hrozeb, pro které diagnostika neexistuje

HORIZON-HLTH-2023-3.17 Pandemic Preparedness and Response: Understanding vaccine induced-immunity

  • X-stage, RIA
  • Zkoumání imunitní reakce po vakcíně – síla, délka, dle věku…

HORIZON-HLTH-2023-DISEASE- 3.18: Immunogenicity of surface proteins of viruses with epidemic potential (Pandemic preparedness research)

  • X-stage, RIA
  • Hodnocení potenciálu tvořit imunitu u povrchových proteinů virů – kromě chřipky a koronavirů

HORIZON-HLTH-202X-DISEASE-3.19: Host-pathogen interactions of infectious diseases with epidemic potential (Pandemic preparedness research)

  • X-stage, RIA
  • Hodnocení vztahu hostitele a viru s ohledem na mezinárodní hrozbu

Destination 4. Ensuring access to innovative, sustainable and high-quality health care

HORIZON-HLTH-2023-CARE- 4.1: Maintaining access to regular care in case of crossborder health emergencies

  • Single-stage, RIA
  • Vyhodnocení a plánování standardní péče v době pandemie

HORIZON-HLTH-2023-CARE- 4.2: A resilient health and care workforce for the future

  • Single-stage, RIA
  • Analýza, management, zlepšování podmínek pracovníků ve zdravotnictví

HORIZON-HLTH-2023-CARE- 4.3: Environmentally sustainable and decarbonised health and care systems

  • Single-stage, RIA
  • Inovativní řešení v nakládání s odpady a snižování emisní stopy

HORIZON-HLTH-2024-CARE- 4.4: Access to health and care services for vulnerable groups

  • Single-stage, RIA
  • Analýza a návrh řešení v rozdílném přístupu ke zdravotnictví – např. Romové

HORIZON-HLTH-2024-CARE- 4.5: Pre-commercial procurement for environmentally sustainable and low-carbon health and care systems

  • Single-stage, PCP
  • Veřejná zakázka na řešení snížení uhlíkové stopy, zelené technologie…

HORIZON-HLTH-2023-CARE- P4: European Partnership on Personalised Medicine

  • Single-stage, Co-fund
  • 100 mil. EUR/projekt (1)

Destination 5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society

HORIZON-HLTH-2023-TOOL- 5.01: Clinical trials of Combined ATMPs

  • Single-stage, RIA
  • Combined ATMPs dle definice EU
  • Pokročilejší stádia výzkumu (kompletní studie bezpečnosti, 2. fáze klinických testů)
  • 8-10 mil. EUR/projekt

HORIZON-HLTH-2023-TOOL- 5.03: Integrated, multi-scale computational models of patient patho-physiology (‘virtual twins’) for personalised disease management

  • Single-stage, RIA
  • Virtual twin patient models
  • Komplexní simulace přenosných i nepřenosných nemocí
  • AI, machine learning, modelling…
  • Příprava modelů, testování

HORIZON-HLTH-2023-TOOL- 5.04: Better integration and use of health-related realworld and research data, including genomics, for improved clinical outcomes, research and innovation

  • Single-stage, RIA
  • Integrace medicínských dat z různých zdrojů
  • Identifikace bariér, návrh řešení, nové nástroje, data management approach

HORIZON-HLTH-2023-TOOL-5.05: Harnessing the potential of real-time data analysis and secure Point-of-Care computing for the benefit of person-centred health and care delivery

  • Single-stage, IA
  • Point-of-care applications
  • Vývoj a testování nových nástrojů – robotika, fotonika, real-time imaging…

HORIZON-HLTH-2024-TOOL-5.02: Bio-printing of living cells for regenerative medicine

  • Single-stage, RIA
  • Preklinická a raně klinická fáze

HORIZON-HLTH-2024-TOOL-5.06: Innovative non-animal human-based tools and strategies for biomedical research

  • Two-stage, RIA
  • Nahrazení zvířecích modelů pokročilými metodami s větším translačním potenciálem

Destination 6. Maintaining an innovative, sustainable and globally competitive health industry

HORIZON-HLTH-2023-IND-6.01: Supporting the uptake of innovative HTA methodology and advancing HTA expertise across EU

  • Single-stage, CSA
  • Health Technology Assessment – hodnocení přínosů a nákladové efektivity zdravotnických technologií
  • Dialog mezi HTA bodies a akademickým prostředím

HORIZON-HLTH-2023-IND- 6.02: Expanding the European Electronic Health Record exchange Format to improve interoperability within the European Health Data Space

  • Single-stage, RIA
  • Vývoj a validace formátů pro přenos pacientských dat

HORIZON-HLTH-2023-IND- 6.04: Modelling and simulation to address regulatory needs in the development of orphan and paediatric medicines

  • Single-stage, RIA
  • Modelování a simulace ve vývoji a klinickém testování dětských léčiv
  • Využití existujících dat jako podkladů pro regulatorní orgány

HORIZON-HLTH-2023-IND- 6.05: Mapping of regulatory requirements for the translation of Advanced Therapy Medicinal Products (ATMP)

  • Single-stage, CSA
  • Mapování současných regulatorních, bezpečnostních, organizačních preklinických a klinických postupů

HORIZON-HLTH-2023-IND- 6.06: Innovation Partnership 2024 – Development procurement and responsible management of new antimicrobials

  • Single-stage, CSA
  • Přípravná fáze pro ustavení partnerství v oblasti AMR – žadatelé mají zmapovat nezbytné podmínky pro ustanovení partnerství

HORIZON-HLTH-2023-IND- 6.07: Development and harmonisation of methodologies for assessing digital health technologies in Europe

  • Single-stage, RIA
  • Vývoj a harmonizace metodologie pro hodnocení digitálních prostředků ve zdravotnictví

HORIZON-HLTH-2024-IND- 6.03: Setting up a European wide collaborative mechanism to support the adoption of innovative health solutions across European regions

  • Single-stage, IA
  • Tvorba ekosystémů na podporu medicínských inovací
  • Umožňuje kaskádové financování

HORIZON-HLTH-2024-IND- 6.08: Developing an EU methodological framework for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)

  • Single-stage, RIA
  • Vývoj metodologie pro používání IVDs

Vyhlášené výzvy

Destination 1 

Personalised blueprint of chronic inflammation in health-to-disease transition

Code: HORIZON-HLTH-2022-STAYHLTH-02-01
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 50
Expected EU contribution per project (EUR million): cca 7
Number of projects expected to be funded: 7

Expected Outcome:

  • Researchers and medical professionals understand the chronic inflammation factors triggering the health-to-disease transition and subsequently provide optimal counselling to citizens for improving their health.
  • Health care professionals have access to and employ objective health indicators of chronic inflammation for monitoring the health status, establishing personalised prevention measures and improving the health outcomes for citizens.
  • Health care professionals have the scientific evidence and understanding of health-to-disease transition to develop and use improved guidelines for personalised prevention strategies to tackle chronic diseases.
  • Citizens are better informed to actively manage their own health, have the tools to maintain their healthy status, improve their health and reduce their risk for developing chronic diseases.

Scope:

Proposals should be of multidisciplinary nature involving all relevant stakeholders and may cover several different stages in the continuum of the innovation path (from translational research to validation of the findings in human studies etc.), as relevant. Proposals are expected to develop and implement data-driven, personalised approaches to identify the drivers of chronic inflammation that may determine the transition from health to pre-symptomatic and early stages of chronic diseases/disorders. The topic does not exclude any diseases/disorders. Proposals should develop personalised diagnosis and/or prevention strategies linked to chronic systemic/local inflammation and assess the effects of different types of interventions and/or their combinations i.e. pharmacological, non-pharmacological, nutritional supplements, diet and life-style modifications, as relevant.

 

Destination 2 

Methods for assessing health-related costs of environmental stressors

Code: HORIZON-HLTH-2022-ENVHLTH-04-01
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 20
Expected EU contribution per project (EUR million): cca 4
Number of projects expected to be funded: 5

Expected Outcome:

  • EU and national public authorities regularly use economic and health modelling in policy impact assessments and policy evaluation, and promote the use of these to other stakeholders;
  • Stakeholders agree on the most relevant population health and quality of life metrics, including DALYs (Disability Adjusted Life Years) or QALYs (Quality Adjusted Life Years), and economic metrics;
  • The stakeholder community follows common guidelines and methodologies for integrative socio-economic assessments and cost-benefit analysis of environmental pollution in Europe.

Scope:

Deaths and disabilities resulting from pollution carry a quantifiable economic cost to society, but there are significant uncertainties in the cost estimates methodologies. There is also paucity of data to evaluate the economic benefits of clean environments. Proposed research activities should mainly aim to improve the calculation of the socio-economic costs (and/or benefits) of health impacts during the life-course associated to environmental stressors, or combinations of these, advance methodological approaches and foster their acceptance as common good practice.

Destination 3

Pandemic Preparedness

Code: HORIZON-HLTH-2022-DISEASE-07-02
Action type: RIA
Opening: 12. 1. 2022
Deadline: 21. 4. 2022
Budget (EUR million): 10
Expected EU contribution per project (EUR million): cca 3
Number of projects expected to be funded: 3

Expected Outcome:

  • The scientific community has better understanding of the biology of the pathogens (virus, bacteria etc.), its transmission, its interaction with humans, animals and plants, in particular in view of emerging threats to human health, such as infectious diseases and anti-microbial resistance.
  • Health care providers and practitioners have access to and use appropriate medical countermeasures, e.g. vaccines, diagnostics, therapeutics and digital solutions.
  • Health authorities have the evidence-base and tools for better public health measures.

Scope:

Member States agreed to step up their coordination in the area of pandemic preparedness research and aim to establish a European partnership on pandemic preparedness (HORIZON-HLTH-2021-DISEASE-04-06: Building a European partnership for pandemic preparedness). key component for the European Health Union will be the establishment of the Health Emergency Preparedness and Response Authority (HERA) for which the Commission will put forward a legislative proposal by the end of 2021. This topic aims to contribute and complement both of these initiatives, notably by addressing priority research and innovation gaps also identified by Member States and that would contribute and support the establishment and work of a potential future Health Emergency Preparedness and Response Authority (HERA). Research focussing on ‘pathogen X’ from threat assessment, horizon scanning for the identification of potential medical countermeasures and innovative technologies, including the development of standardised research protocols would be in the scope of this topic.

Non-communicable diseases risk reduction in adolescence and youth (Global Alliance for Chronic Diseases - GACD)

Code: HORIZON-HLTH-2022-DISEASE-07-03
Action type: RIA
Opening: 12. 1. 2022
Deadline: 21. 4. 2022
Budget (EUR million): 25
Expected EU contribution per project (EUR million): cca 3
Number of projects expected to be funded: 8

Expected Outcome:

  • Health care practitioners and providers in low- and middle-income countries (LMICs) and those in high-income countries (HICs) serving vulnerable populations have access to and use specific guidelines to implement prevention interventions able to support adolescents and young people to decrease future risks of developing NCDs.
  • Public health managers and authorities have access to improved insights and evidences on the NCDs related to behaviours and conditions in youth and adolescence. They establish improved health policies to diminish these risks, including to facilitate the deployment of effective public health interventions.
  • Researchers, clinicians and authorities have an improved understanding of the factors that influence the implementation of preventive actions that address risk behaviours in youth and adolescence.
  • Communities and local stakeholders and authorities are fully engaged in implementing and taking up health interventions and thus contribute to deliver better health.

Scope:

The topic is focused on implementation research about common risk prevention interventions targeting adolescents and youth to reduce the impact of non-communicable diseases (NCDs) in low- and middle-income countries (LMICs) and vulnerable populations in high-income countries (HICs). Proposals should focus on implementation science around evidence-based interventions that promote healthy behaviours, and that have the potential to profoundly reduce the risk of chronic diseases and multimorbidity. Applicants are invited to consider interventions at the individual, family, community (e.g., work or school) or population level. Multi-sectoral approaches and a combination of different types of interventions, including biomedical, digital (such as artificial intelligence and big data), socio-behavioural, and/or structural are encouraged. Proposals should include implementation research outcomes (e.g. feasibility, fidelity and/or adaptation, spread and/or penetration, acceptability, sustainability, uptake, and cost effectiveness) and where relevant, include service outcomes (e.g. efficiency, safety, effectiveness, patient-centeredness, timeliness).

Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)

Code: HORIZON-HLTH-2022-DISEASE-07-01
Action type: CSA
Opening: 12. 1. 2022
Deadline: 21. 4. 2022
Budget (EUR million): 2
Expected EU contribution per project (EUR million): cca 2
Number of projects expected to be funded: 1

Expected Outcome:

  • International research funders are supported by a dynamic and efficient secretariat in their coordination efforts for a rapid research response when a pandemic or a severe epidemic strikes.
  • International research funders can rely on a tested framework underpinning a rapid and effective research response, and as such ensure stronger research preparedness and response for public health emergencies, including in cross-cutting areas such as data sharing, social science, clinical trial networks and others.
  • Research funders, policy makers and the research community are well informed of the activities of GloPID-R members, both as a group and individually.


Scope:

The Global Research Collaboration for Infectious Disease Preparedness (GloPID-R) was established in 2013 and provides a widely recognised platform for infectious disease research funders to work together to better tackle severe epidemics such as Ebola or Zika, as well as global pandemics such as COVID-19. Proposals should foresee administrative and technical support through a secretariat to maintain, but above all to support GloPID-R’s continuous evolution for an optimal value added.

European partnership fostering a European Research Area (ERA) for health research

Code: HORIZON-HLTH-2022-DISEASE-03-01
Action type: Cofund Action
Opening: 12. 1. 2022
Deadline: 21. 4. 2022
Budget (EUR million): 30
Expected EU contribution per project (EUR million): cca 30
Number of projects expected to be funded: 1

Expected Outcome:

  • Research funders, policy-makers and the research community work together in an effective joint approach, including for identifying and prioritising topics of common interest and European benefit, thanks to a trusted governance and effective working modalities.
  • Research funders and policy-makers generate knowledge for cardiovascular diseases, diet related diseases and Nano medical technologies, and have access to and use evidences of the benefit and drawback of health interventions, in particular for optimising clinical management, repurposing, comparative effectiveness, treatment combination or optimisation studies, personalised medicine and avoiding overtreatment.
  • Research funders and policy-makers have removed the main barriers to test health interventions at European level, and thus the research community conducts large-scale investigator-initiated clinical studies (IISs) of various health interventions addressing important public health needs in a seamless way.


Scope:

This new European Partnership will integrate European networks and eco-systems, building on their long-standing experience also expanding towards investigator-initiated clinical studies. It will identify bottlenecks, which hinder multinational clinical studies and propose ways to overcome them. Phase 1 of the Partnership will serve as a transition from diverse scientific research agenda towards a shared scientific agenda which will include the support of investigator-initiated clinical studies. During Phase 2, multinational calls for IICSs and joint calls for other priority areas will be launched in accordance with the decision of the Health Programme Committee taken at the end of Phase 1 on the appropriately shared focus of the Partnership between IICSs and other areas.

 

Destination 4 

Pre-commercial research and innovation procurement (PCP) for building the resilience of health care systems in the context of recovery

Code: HORIZON-HLTH-2022-CARE-08-02
Action type: Pre-commercial Procurement
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 25
Expected EU contribution per project (EUR million): cca 5
Number of projects expected to be funded: 5

Expected Outcome:

  • Public and private procurers in the area of health care procure the competitive development of market-ready, sustainable, innovative solutions (materials, equipment, technologies and systems/practices) which are made in Europe and can improve the preparedness and resilience of health care systems in the context of the recovery;
  • European health and technology industry actors (including start-ups/SMEs) bring to the market secure, interoperable digital health care solutions (complying with relevant ethical and privacy protection standards) which are proven to improve health outcomes and access to care for patients;
  • Procurers facilitate the commercialisation of innovative solutions at a large scale (EU/international) by their successful suppliers through providing them with first customer references for the validation and first pilot deployment in multiple countries and health care settings;
  • Policymakers, health care providers and professionals, patients and their carers – each in their respective areas – exchange and adopt good practices and the best solutions the market can deliver to improve the resilience of health care systems.

Scope:

Pre-commercial procurement (PCP) can boost innovation in health care systems, while building the capacity of providers and increasing resilience and preparedness in the context of cross-border public health emergencies. Pre-commercial procurement actions in the area of health care gather relevant public and private procurers to address a common, unmet need through the cross-border public and private procurement of research and development for demand-driven innovative solutions. Proposals should therefore be based on clearly identified user needs and well-structured work plans, explaining how the procured research and development will contribute to the expected outcomes. In addition, proposals should clearly state the expected health benefits of the solutions that will be developed during the course of the action. In this context, applicants should also consider aspects of accessibility and affordability of the solution, efficiency of the technology when implemented in the relevant contexts and how it contributes to health systems resilience. This topic prioritises areas of health care such as health promotion, preparedness, prevention, surveillance and rapid response to cross-border health threats. Promoting coordination, cooperation and common standards in the procurement of innovation in health care (including emergency procurement) should be at the heart of any proposal submitted as well as facilitating the digital and green transition of EU health systems.

Public procurement of innovative solutions (PPI) for building the resilience of health care systems in the context of recovery

Code: HORIZON-HLTH-2022-CARE-08-03
Action type: Public Procurement of Innovative Solutions
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 15
Expected EU contribution per project (EUR million): cca 5
Number of projects expected to be funded: 3

Expected Outcome:

  • Public and private procurers in the area of health care deploy at a critical scale, innovative, market-ready solutions (materials, technologies and systems/practices), that are relevant to the preparedness and resilience of health care systems;
  • European health and technology industry actors (including start-ups/SMEs) bring to the market secure, interoperable digital health care solutions (complying with relevant ethical and privacy protection standards) which are proven to improve health outcomes and access to care for patients;
  • Procurers facilitate the commercialisation of innovative solutions at a large scale (EU/international) by their successful suppliers through providing them with customer references for the validation and first pilot deployment in multiple countries and health care settings;
  • Policymakers, health care providers and professionals, patients and their carers – each in their respective areas – exchange and adopt good practices and the best solutions the market can deliver to improve the resilience of health care systems.

Scope:

The actions supported will target critical-scale deployment of relevant health care solutions across different regions in Europe by engaging public and/or private procurers from each participating country (at national, regional or local level) that have deployment responsibilities and budget control in the relevant area of care or supply of services. Procurers will specify, purchase and deploy solutions addressing their relevant, shared unmet needs, while engaging together in a supply and demand side dialogue, in order for the deployed solutions to deliver sustainable, new or improved health care services and outcomes, always taking into account patient feedback. Activities covered should include cooperation with policymakers to reinforce the national policy frameworks and mobilise substantial additional national budgets for the PPI, searching support and collaborating with respective coordination and networking projects.

Better financing models for health systems

Code: HORIZON-HLTH-2022-CARE-08-04
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 30
Expected EU contribution per project (EUR million): cca 5
Number of projects expected to be funded: 6

Expected Outcome:

  • Health and social care services and systems have improved governance mechanisms and are more effective, efficient, accessible, resilient, trusted and sustainable, both fiscally and environmentally. Health promotion and disease prevention will be at their heart, by shifting from hospital-centred to community-based, people-centred and integrated health care structures and successfully embedding technological innovations that meet public health needs, while patient safety and quality of services is increased.
  • Health policy and systems adopt a holistic approach (individuals, communities, organisations, society) for the evaluation of health outcomes and value of public health interventions, the organisation of health care, and decision-making.
  • Decision and policymakers in the field of health care avail of new approaches to financial planning and financing mechanisms that provide flexibility to stretched health budgets, including alternative procurement and contractual methods;
  • Decision and policymakers in the field of health care apply cost-effective spending strategies based on the optimisation of the use of resources, while maintaining or improving health outcomes in an equitable way;
  • Decision and policymakers in the field of health care access tools that enable them to better remunerate, contract and incentivise health care professionals and providers;
  • Decision and policymakers in the field of health care take evidence-based and socially equitable health care financial decisions.

Scope:

Research and innovation should tackle the challenges of financing health care services in the EU by addressing one or more of the following:

  • Financing of health care – development of new cost-effective models for financing and reimbursement, including incentive mechanisms and outcome-based financing in order to promote good performance of the health care systems.
  • Financing of preventive health care – novel models and appropriate structure of financial incentives for effective health promotion and disease prevention, financial incentives for stronger co-operation between primary care and public health services, long-term sustainable financing mechanism for local- and municipality-run promotion programmes and the assessment of personal health risk behaviour and its potential impact on health costs.
  • Innovative purchasing and contract methods – new strategies for contracting provision of health care services (public sector hired services) as well as solutions to better assess provision capacity and quality, to assess markets, and cost-effectiveness as well as equal access of contracting-out services. This can help align the incentives of providers with those of patients and the public good.
  • New and improved tools for better design of incentives for health care professionals – incentives that minimise differentiation between services and “cream-skimming” by patients, fostering better health care planning, optimized use of health care services and avoidance of resources’ overconsumption and -waste.

European partnership on transforming health and care systems

Code: HORIZON-HLTH-2022-CARE-10-01
Action type: Cofund Action
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 100
Expected EU contribution per project (EUR million): cca 100
Number of projects expected to be funded: 1

Expected Outcome:

  • Researchers across European countries and regions are engaged in enhanced collaborative research on transforming health and care systems;
  • Health and care authorities, policymakers and other stakeholders use the research results to develop evidence-based strategies and policies on transforming health care systems and learn from good practices of European countries and regions;
  • Health and care providers and professionals implement innovative ways of delivering care and maintaining population health;
  • Health and care authorities, policymakers and other stakeholders plan and carry out efficient investments in health and care systems at national/regional level to use innovative solutions and care models;
  • An increased number of innovators and stronger local/regional ecosystems of stakeholders are in place and facilitate uptake of successful innovations for health and care;
  • Citizens and health and care professionals have increased digital and health literacy;
  • Countries cooperate better and use context-specific knowledge and evidence to make their health and care systems more resilient with respect to upcoming needs and crises.

The Partnership is open to all EU Member States, as well as to countries associated to Horizon Europe and will remain open to those countries wanting to join. It should include the following actors:

  • Ministries in charge of R&I policy, as well as national and regional R&I and technology funding agencies and foundations;
  • Ministries in charge of R&I policy, as well as national and regional R&I and technology funding agencies and foundations;

The European Partnership on transforming health and care systems should be implemented through a joint programme of activities ranging from research to coordination and networking activities, including training, demonstration, piloting and dissemination activities, to be structured along the following main building blocks:

  • Joint implementation of the SRIA;
  • Joint annual calls for R&I activities, applied R&I, pilots, twinning projects;
  • Joint annual calls for experimental development and innovation funding, co-creation, involvement of end-users, new concepts of care and innovative solutions for supporting health according to WHO definition; development of ecosystems, business models;
  • Capacity building activities;
  • Activities to increase health and digital literacy among citizens and health care practitioners;
  • Flanking measures.

Destination 5

Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers

Code: HORIZON-HLTH-2022-TOOL-11-01
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 60
Expected EU contribution per project (EUR million): cca 10
Number of projects expected to be funded: 6

Expected Outcome:

  • Diagnostics industries move towards market approval for companion diagnostics.
  • Regulatory authorities approve companion diagnostics and make recommendations for the prescription of existing drugs.
  • Health care providers use biomarkers with existing pharmaceuticals to treat more efficiently and cost-effectively patients, with less adverse effects.

Scope:

The applicants should perform the clinical validation of qualified biomarkers (not limited to molecular biomarkers) that will enable the identification of appropriate patients to ensure an effective and efficient use of existing pharmaceuticals in the treatment of major diseases and conditions. The relevant biomarkers should allow providing the right medicinal product, at the right dose and the right time, according to the concept of personalised medicine, taking into account, among others, differences of sex, age, ethnicity and gender identity. This topic refers to medicines that are already on the market and not to the validation of biomarkers for the development of new medicinal products. It addresses broadly prescribed medicines for major diseases and conditions, including but not limited to cardiovascular diseases. A condition is that preliminary studies or publications have demonstrated that the pharmaceuticals considered are efficient in less than 50% of the population treated. This topic excludes cancer and rare disease treatments. The applicants should consider existing guidelines, standards and regulations, as appropriate. Synergies with relevant European Research Infrastructures are encouraged.

New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment

Code: HORIZON-HLTH-2022-TOOL-11-02
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 35
Expected EU contribution per project (EUR million): cca 7
Number of projects expected to be funded: 5

Expected Outcome:

  • Health regulatory bodies and/or Health Technology Assessment (HTA) bodies adopt optimised data-driven methodologies for the effective use of real-world data (including omics data), and/or synthetic data derived from digital twins and advanced computational methods (such as modelling and simulation or approaches based on machine learning/AI), for the assessment of medicinal products and/or digital health innovations.
  • Health regulatory authorities and bodies (e.g. medicines agencies, HTA bodies, notified bodies for medical devices) use optimised guidelines for the development and assessment of medicinal products and/or medical devices including digital health innovations.
  • Health regulatory authorities and bodies across Europe are trained in data-driven decision making using emerging data types.

Scope:

With the emerging use of real-world data (RWD) and synthetic data by the pharmaceutical industry and medical devices industry, regulators and HTA bodies need to perform targeted validation of claims through independent analysis. The principal aim of this topic is to address the data needs of health regulatory bodies and HTA bodies across the EU, as outlined in the recently published “HMA-EMA Joint Big Data Taskforce Phase II report: ‘Evolving Data-Driven Regulation’”and its associated DARWIN (Data Analysis and Real World Interrogation Network) project. Proposals should involve researchers who are specialised in the use of real-world data and/or synthetic data to evaluate medicinal products and/or health care digital innovation products and services. Proposals should involve national competent authorities (national health care product regulatory bodies and/or medical device notified bodies) and could involve citizens and patients’ representatives where relevant. Proposals should include capacity-building efforts to address inequalities of health regulatory processes across Europe. This should comprise education and training activities and sharing of best practices.

Destination 6

Enhancing cybersecurity of connected medical devices

Code: HORIZON-HLTH-2022-IND-13-01
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 20
Expected EU contribution per project (EUR million): cca 6
Number of projects expected to be funded: 3

Expected Outcome:

  • Stakeholders (e.g. manufacturers, suppliers, health care providers, integrators, operators) apply measures to identify and address cybersecurity risks and gaps in connected medical devices.
  • Stakeholders adopt and use newly developed risk benefit analysis schemes and capabilities for cybersecurity of connected medical devices.
  • Stakeholders adopt and use newly developed methodologies and toolboxes for ensuring cybersecurity of connected medical devices by design.
  • Stakeholders adopt and use fit for purpose guidance covering challenges posed by connected medical devices, including software.

Scope:

The proposals are expected to help strengthening cybersecurity maintaining the performance of medical devices while preserving or enhancing safety, security and data confidentiality, integrity and availability. The applicants should tackle the cybersecurity issue of connected medical devices and in vitro diagnostic medical devices, in particular those that are connected to the internet, allow remote access to data and exchange private or proprietary data.

Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation

Code: HORIZON-HLTH-2022-IND-13-02
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 30
Expected EU contribution per project (EUR million): cca 7
Number of projects expected to be funded: 4

Expected Outcome:

  • The EU contributes strongly to global standards for health data through enhancement of common European standards for health data (including medical imaging data) by researchers and innovators. Researchers and innovators contribute to GDPR compliant guidelines and rules for data anonymisation.
  • Innovators have access to advanced secure data processing tools to test and develop robust data-driven digital solutions and services in response to the needs of researchers, clinicians and health systems at large.
  • Cross-border health data hubs further facilitate the innovation process by providing secure, trustable testing environments for innovators.
  • Clinicians, patients and individuals use a larger variety of high quality data tools and services for wellbeing, prevention, diagnosis, treatment and follow-up of care.
  • Researchers and innovators have more opportunities for testing and developing GDPR compliant data driven solutions based on actual needs of the health care environments.

Scope:

The proposals are expected to scale up multi-party computation, data anonymisation techniques and synthetic data generation. To ensure privacy, the data analytics should be conducted in a distributed way among processors that grant third parties access to analysis outcomes but not to the underlying data. The developers should have access to distributed testing data sources and cloud and computing resources at large scale, with a view to improving the speed and robustness of multi-party computation solutions for innovators. The aim is to allow secure GDPR-compliant data processing for research, and clinical purposes.

New pricing and payment models for cost-effective and affordable health innovations

Code: HORIZON-HLTH-2022-IND-13-03
Action type: RIA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 15
Expected EU contribution per project (EUR million): cca 5
Number of projects expected to be funded: 3

Expected Outcome:

  • Health authorities and insurers adopt new payment models for health technologies, including pharmaceuticals.
  • Health industries anticipate better the marketing conditions for innovative health technologies. Patients and health care providers have faster access to innovative health technologies.
  • Health authorities, insurers and health care providers have affordable innovative health technologies both on short and longer terms.

Scope:

Applicants are requested to propose new value-based pricing and reimbursement models that can help ensure equitable access to effective, efficient, affordable, and sustainable health technologies, including medicines, while supporting innovation and industrial competitiveness. The research should tackle the issue globally and be based on a multidisciplinary approach combining economic science, political science and sociology. The proposals should not be limited to the study of cost-effectiveness analyses and thresholds in decision-making. They should also address long term intended and unintended consequences of pricing and reimbursement decisions. Moreover, they should consider the potential limitation of no-coverage decision for products with high budgetary impact. Applicant consortia should include regulators and public entities that are in charge of attributing value tags to health technologies, negotiating with health technology manufacturers and/or reimbursing medical costs.

Setting up a European Smart Health Innovation Hub

Code: HORIZON-HLTH-2022-IND-13-04
Action type: CSA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 2
Expected EU contribution per project (EUR million): cca 2
Number of projects expected to be funded: 1

Expected Outcome:

  • Empowered patients and citizens of all ages, gender, social and economic background adopt and use digital tools to monitor their health status independently.
  • A strong European ecosystem is created by innovators in the health domain, including, but not limited to SMEs, Research and Technology Organisations (RTOs), accelerators, incubators, (European) Digital Innovation Hubs (EDIH), European Reference Sites of the EIP-AHA and Knowledge Hubs, involving end-users.
  • Public and private entities adopt the innovations of European digital health companies, especially SMEs and mid-caps, enhancing their sustainability and resilience.
  • Citizens, patients, health practitioners and facilities, public and private actors access and make use of sustainable EU-wide reference repository of digitally-enabled innovative solutions addressing all health related sectors, areas and segments, with particular focus on self-management and prevention.

Scope:

Coordination and support is needed to: i) create a pan-European operational network as a mechanism (a European Smart Health Innovation Hub) that can assess and promote Smart Health initiatives; ii) stimulate the demand-side and the uptake of Smart Health products and services; and iii) support the development of Smart Health products and services. Applicants should propose activities addressing the need to bring together different actors, working on innovative digital health solutions and to reinforce their collaboration, exchange and efforts on scaling-up digital health solutions across Europe. Applicants should link various existing repositories of digital health solutions, which are already deployable as part of different EU projects and initiatives.

Setting up a European Electronic Health Record Exchange Format (EEHRxF) Ecosystem

Code: HORIZON-HLTH-2022-IND-13-05
Action type: CSA
Opening: 6. 10. 2021
Deadline: 21. 4. 2022
Budget (EUR million): 2
Expected EU contribution per project (EUR million): cca 2
Number of projects expected to be funded: 1

Expected Outcome:

  • Individuals, researchers, health services and the workforce across borders in the EU Digital Single Market use significantly improved and interoperable cross-border digital health solutions thanks to sophisticated ICT toolbox, representative use case applications, a Pan-European ecosystem of early adopters, and a framework for sustainability and exploitation. These will also contribute to the European Health Data Space.
  • Individuals have an improved level of accessibility, control and portability of health data, including donation for research across Europe and jurisdictions.
  • Policy makers and members of the eHealth Network are better informed and advised regarding potential evolutions of the EEHRxF and its extension to other uses cases.
  • Different target populations such as designers, developers, health care professionals, and individuals have access to exploitation and capacity building support, such as training material, dedicated tools, guidelines, mentorship and collaboration programs.

Scope:

Interoperability of Electronic Health Record is key for the exchange and the portability of health data in view of better health outcomes and treatments. The EU has supported projects to ensure cross-border sharing of health data and, in 2019, adopted a Recommendation on EEHRxF. There is a need to continue supporting the uptake of new use cases (i.e. laboratory results, medical imaging and reports, and hospital discharge reports) and take on board possible new requirements, and ultimately to bring together policy actors and stakeholders.

Používáte starou verzi internetového prohlížeče. Doporučujeme aktualizovat Váš prohlížeč na nejnovější verzi.

Další info